Caldwell Sutter Capital, Inc. Ultragenyx Pharmaceutical Inc. Transaction History
Caldwell Sutter Capital, Inc.
- $218 Billion
- Q2 2025
A detailed history of Caldwell Sutter Capital, Inc. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Caldwell Sutter Capital, Inc. holds 123 shares of RARE stock, worth $3,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
123
Previous 123
-0.0%
Holding current value
$3,450
Previous $4.45 Million
0.4%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding RARE
# of Institutions
337Shares Held
89.9MCall Options Held
1.08MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA10MShares$280 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$157 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.16MShares$117 Million0.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$90.3 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$73.4 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $1.96B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...